Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Oisquercq – page 76

1 851 clinical trials in Oisquercq, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Oisquercq at a glance
1 851
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 851 trials in Oisquercq

Open in trial search

Study Comparing DB-1303 and Chemotherapy for Patients with HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Dualitybio Inc.

Migraine+2

Not recruiting

Study on Atogepant for Treating Migraine in Patients: Evaluating Effectiveness and Safety

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Atogepant
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Vitiligo

Not recruiting

Study of ritlecitinib (50 mg and 100 mg daily) compared to placebo in adults with nonsegmental vitiligo

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Pfizer Inc.

Vitiligo

Not recruiting

Study on the Effects of Upadacitinib in Adults and Adolescents with Non-Segmental Vitiligo Eligible for Systemic Treatment

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Upadacitinib
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Crohn's disease

Not recruiting

Study of Oral Ozanimod as Maintenance Treatment for Adults with Moderate to Severe Crohn's Disease

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Ozanimod
  • Sponsor:Celgene International II S.a.r.l.

Study on the Effects of Astegolimab and Drug Combination for Patients with Chronic Obstructive Pulmonary Disease (COPD)

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Sponsor:Genentech Inc.

Vitiligo

Not recruiting

Study on the Effectiveness of Povorcitinib for Adults with Nonsegmental Vitiligo

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Povorcitinib
  • Sponsor:Incyte Corp.

Dyslipidaemia

Not recruiting

Study of Evolocumab to Prevent Heart Disease Events in High-Risk Patients Without Previous Heart Attack or Stroke

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Evolocumab
  • Sponsor:Amgen Inc.

Dermatomyositis

Not recruiting

Study on the Effects of Human Normal Immunoglobulin in Adults with Dermatomyositis

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Human Normal Immunoglobulin
  • Sponsor:CSL Behring LLC

Study on Long-Term Safety of Cendakimab for Adults and Adolescents with Eosinophilic Esophagitis

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Cendakimab
  • Sponsor:Celgene International II S.a.r.l.

Study of resmetirom (MGL-3196) in patients with Non-Alcoholic Steatohepatitis (NASH) to prevent liver damage and disease progression

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Resmetirom
  • Sponsor:Madrigal Pharmaceuticals Inc.

Study on the Effects of Semaglutide in Patients with Non-Alcoholic Steatohepatitis (NASH) and Fibrosis Stages 2 or 3

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Semaglutide
  • Sponsor:Novo Nordisk A/S

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Oisquercq

What the registry says about research in the country

01 Infectious Disease Research

Clinical investigations focusing on recurrent orofacial herpes infections, evaluating innovative therapeutic approaches for patients experiencing frequent outbreaks.

  • Herpes Management
  • Outbreak Prevention
  • Treatment Efficacy

The study aims to assess a new therapeutic intervention for reducing the frequency of herpes episodes through a controlled, double-blind methodology.

02 Viral Disease Control

Research examining the effectiveness of preventive treatments for patients who experience six or more herpes episodes annually.

  • Viral Suppression
  • Long-term Management
  • Quality of Life Impact

The trial evaluates treatment outcomes over a 12-month period, focusing on reducing infection recurrence rates.

03 Clinical Therapeutics

Investigation of placebo-controlled interventions designed to address recurring viral infections affecting the orofacial region.

  • Treatment Innovation
  • Symptom Control
  • Patient Response

This research emphasizes the development of effective strategies for managing frequent herpes outbreaks.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.